Qiaohong Qin

Xi'an, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Hepatocyte-Specific Knockout of YAP Protects Against Atherosclerosis via Inhibition of ANGPTL3 in Mice.

Hepatocyte-Specific Knockout of YAP Protects Against Atherosclerosis via Inhibition of ANGPTL3 in Mice.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: February 26, 2026

Hepatocyte-specific yes-associated protein knockout exacerbates non-alcoholic steatohepatitis by upregulating PCSK9.

Hepatocyte-specific yes-associated protein knockout exacerbates non-alcoholic steatohepatitis by upregulating PCSK9.

Journal: Journal of gastroenterology

Published: July 29, 2025

YAP-mediated macrophage polarization is involved in progression of atherosclerosis.

YAP-mediated macrophage polarization is involved in progression of atherosclerosis.

Journal: European journal of pharmacology

Published: March 16, 2025

Yes-Associated Protein in Hepatocytes Protects Against Early Alcohol-Associated Liver Disease.

Yes-Associated Protein in Hepatocytes Protects Against Early Alcohol-Associated Liver Disease.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: December 17, 2024

MiR-365-3p is a negative regulator in IL-17-mediated asthmatic inflammation.

MiR-365-3p is a negative regulator in IL-17-mediated asthmatic inflammation.

Journal: Frontiers in immunology

Published: May 26, 2022

α-Asarone alleviates allergic asthma by stabilizing mast cells through inhibition of ERK/JAK2-STAT3 pathway.

α-Asarone alleviates allergic asthma by stabilizing mast cells through inhibition of ERK/JAK2-STAT3 pathway.

Journal: BioFactors (Oxford, England)

Published: May 14, 2022

Roles of Yes-associated protein and transcriptional coactivator with PDZ-binding motif in non-neoplastic liver diseases.

Roles of Yes-associated protein and transcriptional coactivator with PDZ-binding motif in non-neoplastic liver diseases.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: April 04, 2022

Genetically modified rabbit models for cardiovascular medicine.

Genetically modified rabbit models for cardiovascular medicine.

Journal: European journal of pharmacology

Published: January 08, 2022

Inhibitors of the MAPK/ NF-κB pathway attenuate the upregulation of the ETB receptor mediated by high glucose in vascular smooth muscle cells.

Inhibitors of the MAPK/ NF-κB pathway attenuate the upregulation of the ETB receptor mediated by high glucose in vascular smooth muscle cells.

Journal: Peptides

Published: October 10, 2021

Angiotensin II upregulates endothelin receptors through the adenosine monophosphate-activated protein kinase/sirtuin 1 pathway in vascular smooth muscle cells.

Angiotensin II upregulates endothelin receptors through the adenosine monophosphate-activated protein kinase/sirtuin 1 pathway in vascular smooth muscle cells.

Journal: The Journal of pharmacy and pharmacology

Published: May 23, 2021

Ferroptosis as a new therapeutic opportunity for nonviral liver disease.

Ferroptosis as a new therapeutic opportunity for nonviral liver disease.

Journal: European journal of pharmacology

Published: February 11, 2021

Tetrahydroxystilbene glucoside attenuated homocysteine-upregulated endothelin receptors in vascular smooth muscle cells via the ERK1 /2 /NF-κB signaling pathway.

Tetrahydroxystilbene glucoside attenuated homocysteine-upregulated endothelin receptors in vascular smooth muscle cells via the ERK1 /2 /NF-κB signaling pathway.

Journal: Phytotherapy research : PTR

Published: August 28, 2020

Showing 1-12 of 19

Last Updated: 09/26/2026